Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2011

View Archived Issues

LIPN gene mutation correlates with late-onset autosomal recessive ichthyosis

HRA Pharma and ASKA Pharmaceutical enter licensing agreement in Japan for ellaOne

Novel phosphodiesterase 10A inhibitors designed

New sponge-derived anticancer polyketides described

Daiichi Sankyo presents novel erythropoietin production enhancers

InterMune provides update on development and commercialization of Esbriet

Oncothyreon begins phase II portion of phase I/II trial of PX-866 with cetuximab

Initiation of phase II study triggers milestone payment from Bristol-Myers Squibb to AMRI

Preclinical data support further development of PF-4348235 for treatment of COPD

Findings disclosed from two phase II trials of NXL-104/ceftazidime

Nexvax-2 vaccine is safe and bioactive in phase I trial in celiac disease

Centella Therapeutics gains exclusive rights to antitumor agent CEN-209

FDA approves IND for phase I trial of PWT-33597

Aastrom and CPC Clinical Research enter agreement for phase III REVIVE program of ixmyelocel-T

FLAME study shows enhanced stroke recovery with fluoxetine

Dynavax completes 12-month follow-up in phase III Heplisav trial

Active Biotech's ABR-215757 improves SLE symptoms in exploratory phase II trial

GSK presents new bromodomain inhibitors

Phase II extension data encouraging for Derma Sciences' DSC-127 in diabetes-related foot ulcers

EV-71 vaccine against hand, foot and mouth disease shows promise in phase I trial

Futurechem presents new beta-amyloid production inhibitors

Lytix Biopharma completes two phase I/IIa trials of topical antimicrobial drug Lytixar

NHLBI stops AIM-HIGH study of niacin added to simvastatin early

Ellavie spray approved in Sweden to treat symptoms of menopause

Zeria presents data showing efficacy of Acofide in treatment of functional dyspepsia

German authorities approve Sativex for treatment of spasticity due to MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...